Luke et al (2019) retrospectively assessed BRAF‐mutant metastatic melanoma patients treated with immunotherapies (nivolumab/ipilimumab or aPD‐1) or BRAF/MEKi in the community oncology setting. Here, BRAF is linked to metastatic melanoma.